OncoMatch/Clinical Trials/NCT06065813
Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Is NCT06065813 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab for non-small cell lung cancer.
Treatment: Toripalimab — Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Patients with known EGFR mutations ... are excluded; non-squamous carcinoma patients need to know the status of EGFR ... mutations
Required: ALK fusion
Patients with known ... ALK translocations are excluded; non-squamous carcinoma patients need to know the status of ... ALK mutations
Required: PD-L1 (CD274) expression (tissue submission required; no threshold specified)
Agree to provide PD-L1 immune tissue sections and corresponding pathology reports for biomarker evaluation
Disease stage
Required: Stage IIA, IIB, IIIA
Histologically confirmed resectable stage IIA-IIIA NSCLC without prior treatment; Locally advanced unresectable or metastatic disease [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Early NSCLC with prior systemic anticancer therapy, including experimental drug therapy
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Lab requirements
Blood counts
anc ≥ 1500/μl; plt ≥ 100000/μl; hb ≥ 10.0g/dl; in、rpt、aptt≤1.5×uln
Kidney function
cr ≤ 1.5 × uln or crcl ≥ 60 ml/min (use cock-gault formula)
Liver function
tb ≤ 1.5 × uln (for patients with total bilirubin levels > 1.5 × uln, direct bilirubin is within normal limits); ast and alt ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify